Free Trial

Enanta Pharmaceuticals Q3 2023 Earnings Report

Enanta Pharmaceuticals logo
$6.28 +0.42 (+7.17%)
(As of 12/20/2024 05:16 PM ET)

Enanta Pharmaceuticals EPS Results

Actual EPS
-$1.86
Consensus EPS
-$2.38
Beat/Miss
Beat by +$0.52
One Year Ago EPS
N/A

Enanta Pharmaceuticals Revenue Results

Actual Revenue
$18.89 million
Expected Revenue
$15.88 million
Beat/Miss
Beat by +$3.01 million
YoY Revenue Growth
N/A

Enanta Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

This Crypto Is Set to Explode in December (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

Enanta Pharmaceuticals Earnings Headlines

FY2025 Earnings Forecast for ENTA Issued By Leerink Partnrs
This Crypto Is Set to Explode in December
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Evercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals (ENTA) Gets a Hold from Oppenheimer
See More Enanta Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA), a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

View Enanta Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings